The antiproliferative effect of somatostatin analogs: clinical relevance in patients with neuroendocrine gastro-entero-pancreatic tumours.
- Author
- C Verslype, S Carton, I Borbath, T Delaunoit, P Demetter, G Demolin, A Hendlisz, Piet Pattyn (UGent) , S Pauwels, Marc Peeters (UGent) , G Roeyen, P Van Hootegem, JL Van Laethem and E Van Cutsem
- Organization
- Abstract
- Somatostatin analogs (SSAs) have an important role in the management of patients with neuroendocrine tumours of the gastrointestinal tract and pancreas (GEP NETs). These compounds can control the symptoms induced by the production of hormones and peptides. The antiproliferative effects of SSAs and especially tumour shrinkage are less obvious in patients with GEP NETS than in those with acromegaly. However, based upon phase II experience there is a strong suggestion of a disease stabilizing effect of SSAs in selected patients. Those patients with a progressive, non-functional GEP NET, positive octreotide scintigraphy, a low proliferation index and in the absence of surgical options may benefit from a first-line medical therapy with SSAs. The exploration of the mechanisms of this effect are unclear and hampered by the lack of suitable preclinical models. The better understanding of the tumour biology of GEP NETS, together with the development of new SSAs with better affinity on all somatostatin receptors, represent an unmet medical need.
- Keywords
- somatostatin analogs, neuroendocrine tumors, antiproliferative effect, MALIGNANT CARCINOID-SYNDROME, CELL-LINE, OCTREOTIDE ACETATE, IN-VITRO, LANREOTIDE, EFFICACY, PROLIFERATION, GLUCAGONOMA, INHIBITION, MANAGEMENT
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-687674
- MLA
- Verslype, C., et al. “The Antiproliferative Effect of Somatostatin Analogs: Clinical Relevance in Patients with Neuroendocrine Gastro-Entero-Pancreatic Tumours.” ACTA GASTRO-ENTEROLOGICA BELGICA, vol. 72, no. 1, 2009, pp. 54–58.
- APA
- Verslype, C., Carton, S., Borbath, I., Delaunoit, T., Demetter, P., Demolin, G., … Van Cutsem, E. (2009). The antiproliferative effect of somatostatin analogs: clinical relevance in patients with neuroendocrine gastro-entero-pancreatic tumours. ACTA GASTRO-ENTEROLOGICA BELGICA, 72(1), 54–58.
- Chicago author-date
- Verslype, C, S Carton, I Borbath, T Delaunoit, P Demetter, G Demolin, A Hendlisz, et al. 2009. “The Antiproliferative Effect of Somatostatin Analogs: Clinical Relevance in Patients with Neuroendocrine Gastro-Entero-Pancreatic Tumours.” ACTA GASTRO-ENTEROLOGICA BELGICA 72 (1): 54–58.
- Chicago author-date (all authors)
- Verslype, C, S Carton, I Borbath, T Delaunoit, P Demetter, G Demolin, A Hendlisz, Piet Pattyn, S Pauwels, Marc Peeters, G Roeyen, P Van Hootegem, JL Van Laethem, and E Van Cutsem. 2009. “The Antiproliferative Effect of Somatostatin Analogs: Clinical Relevance in Patients with Neuroendocrine Gastro-Entero-Pancreatic Tumours.” ACTA GASTRO-ENTEROLOGICA BELGICA 72 (1): 54–58.
- Vancouver
- 1.Verslype C, Carton S, Borbath I, Delaunoit T, Demetter P, Demolin G, et al. The antiproliferative effect of somatostatin analogs: clinical relevance in patients with neuroendocrine gastro-entero-pancreatic tumours. ACTA GASTRO-ENTEROLOGICA BELGICA. 2009;72(1):54–8.
- IEEE
- [1]C. Verslype et al., “The antiproliferative effect of somatostatin analogs: clinical relevance in patients with neuroendocrine gastro-entero-pancreatic tumours.,” ACTA GASTRO-ENTEROLOGICA BELGICA, vol. 72, no. 1, pp. 54–58, 2009.
@article{687674,
abstract = {{Somatostatin analogs (SSAs) have an important role in the management of patients with neuroendocrine tumours of the gastrointestinal tract and pancreas (GEP NETs). These compounds can control the symptoms induced by the production of hormones and peptides. The antiproliferative effects of SSAs and especially tumour shrinkage are less obvious in patients with GEP NETS than in those with acromegaly. However, based upon phase II experience there is a strong suggestion of a disease stabilizing effect of SSAs in selected patients. Those patients with a progressive, non-functional GEP NET, positive octreotide scintigraphy, a low proliferation index and in the absence of surgical options may benefit from a first-line medical therapy with SSAs. The exploration of the mechanisms of this effect are unclear and hampered by the lack of suitable preclinical models.
The better understanding of the tumour biology of GEP NETS, together with the development of new SSAs with better affinity on all somatostatin receptors, represent an unmet medical need.}},
author = {{Verslype, C and Carton, S and Borbath, I and Delaunoit, T and Demetter, P and Demolin, G and Hendlisz, A and Pattyn, Piet and Pauwels, S and Peeters, Marc and Roeyen, G and Van Hootegem, P and Van Laethem, JL and Van Cutsem, E}},
issn = {{0001-5644}},
journal = {{ACTA GASTRO-ENTEROLOGICA BELGICA}},
keywords = {{somatostatin analogs,neuroendocrine tumors,antiproliferative effect,MALIGNANT CARCINOID-SYNDROME,CELL-LINE,OCTREOTIDE ACETATE,IN-VITRO,LANREOTIDE,EFFICACY,PROLIFERATION,GLUCAGONOMA,INHIBITION,MANAGEMENT}},
language = {{eng}},
number = {{1}},
pages = {{54--58}},
title = {{The antiproliferative effect of somatostatin analogs: clinical relevance in patients with neuroendocrine gastro-entero-pancreatic tumours.}},
volume = {{72}},
year = {{2009}},
}